ATI-50002

DRUG3 trials

Sponsors

Aclaris Therapeutics, Inc.

Conditions

Alopecia AreataAlopecia TotalisAlopecia Totalis (AT)Alopecia UniversalisAlopecia Universalis (AU)Androgenetic Alopecia

Phase 2

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

CompletedNCT03315689

Aclaris Therapeutics, Inc.Alopecia Totalis (AT), Alopecia Universalis (AU)

Start: 2017-12-14End: 2019-06-20Updated: 2020-07-02

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

CompletedNCT03495817

Aclaris Therapeutics, Inc.Androgenetic Alopecia

Start: 2018-03-22End: 2019-10-30Updated: 2020-12-09

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

CompletedNCT03551821

Aclaris Therapeutics, Inc.Alopecia Areata, Alopecia Totalis, Alopecia Universalis

Start: 2018-04-11End: 2018-11-06Updated: 2019-12-11